Misti Marsh, NP
Nurse Practitioner · Newburgh, INNPI 1467172387
Payments from drug & device makers
Across 184 payments — averaging $16.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$424
- Lilly USA, LLC$223
- Novo Nordisk$213
- Axsome Therapeutics, Inc.$206
- Sumitomo Pharma America, Inc.$179
- AstraZeneca$139
- plus $2K from 34 others
What the payments were for
- Food & beverage$3,070100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 25 | $424 |
| Lilly USA, LLC | 19 | $223 |
| Novo Nordisk | 15 | $213 |
| Axsome Therapeutics, Inc. | 14 | $206 |
| Sumitomo Pharma America, Inc. | 9 | $179 |
| AstraZeneca | 5 | $139 |
| Medtronic | 7 | $138 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $119 |
| GSK | 5 | $96 |
| Exact Sciences | 6 | $92 |
| Corium, LLC | 8 | $85 |
| Novartis | 5 | $84 |
| 180 Medical, Inc. | 4 | $84 |
| Phathom Pharmaceuticals, Inc. | 7 | $82 |
| Bayer | 5 | $77 |
| Merck | 4 | $72 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $69 |
| Tolmar, Inc. | 3 | $65 |
| Astellas Pharma US Inc | 4 | $60 |
| Pfizer | 3 | $53 |
| Myovant Sciences Inc. | 2 | $50 |
| C. R. Bard, Inc. & Subsidiaries | 1 | $49 |
| Verona Pharma, Inc. | 2 | $39 |
| Urovant Sciences Inc | 2 | $36 |
| Otsuka America Pharmaceutical, Inc. | 2 | $34 |
| Inspire Medical Systems, Inc. | 2 | $31 |
| Boehringer Ingelheim | 2 | $30 |
| Johnson & Johnson | 2 | $29 |
| Accord Healthcare, Inc. | 1 | $24 |
| Myriad Genetic Laboratories, Inc. | 1 | $22 |
| Tolmar Pharmaceuticals, Inc. | 1 | $20 |
| Endo Pharmaceuticals Inc. | 1 | $20 |
| Lundbeck LLC | 1 | $18 |
| Alnylam Pharmaceuticals Inc. | 1 | $18 |
| Viatris Specialty LLC | 1 | $17 |
| Coloplast | 1 | $16 |
| Amgen | 1 | $16 |
| Dexcom, Inc. | 1 | $15 |
| Mylan Specialty L.p. | 1 | $14 |
| Organon | 1 | $9 |
How this compares
$3,070 in reported general payments places this provider in the 85th percentile of 2,724 nurse practitioner providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GemtesaVibegron | 34 | $22,994 |
| MyrbetriqMirabegron | 15 | $13,326 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 11 | $1,953 |
| Estradiol | 22 | $1,079 |
| Gabapentin | 65 | $697 |
| Cefdinir | 35 | $685 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 73 | $570 |
| Potassium Chloride | 22 | $543 |
| Trospium Chloride | 11 | $436 |
| Tamsulosin Hcl | 51 | $405 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 34 | $365 |
| Doxycycline Hyclate | 43 | $327 |
| Cephalexin | 45 | $239 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 11 | $238 |
| Losartan Potassium | 32 | $236 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Gemtesa | $179 | $22,99434 claims |
| Astellas Pharma US IncMyrbetriq | $60 | $13,32615 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,724 nurse practitioner providers in Indiana.
Other nurse practitioner in Newburgh
- Kimberly BurkNewburgh$27K
- Shannon KratzerNewburgh$12K
- Elise SchuttNewburgh$10K
- Kristi OrbaughIndianapolis$1.3M
- Kimberly EadsPlainfield$302K
- Sean GoddardFort Wayne$180K
- Kacy RogersIndianapolis$77K
- Kristine TaylorFort Wayne$69K
- Brittany SavageIndianapolis$51K
- Monica HaugerTrafalgar$47K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.